Across all trials, the proportion of non-White racial groups showed an increasing trend over time, rising from 19.4% for trials initiated before 2011 to 25.1% during 2011–2015 and further to 26.2% after 2015 ( Table 4 ).
← all excerpts
Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors.
1
—
—